FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch

[06-02-2016] The U.S. Food and Drug Administration (FDA) is investigating the risk of serious burns and potential permanent scarring with the use of Zecuity (sumatriptan iontophoretic transdermal system) patch for migraine headaches.

Source: FDA Center for Drug Evaluation and Research - What's New - July 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news